Evinacumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Evinacumab
Monoclonal antibody
Type?
SourceHuman
TargetAngiopoietin-like 3 (ANGPTL3)
Clinical data
SynonymsREGN1500
Routes of
administration
subcutaneously (SC) or intravenously (IV)
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6480H9992N1716O2042S46
Molar mass146.1 kg/mol g·mol−1

Evinacumab (REGN1500) is a monoclonal antibody designed for the treatment of dyslipidemia.[1]

This drug was developed by Regeneron Pharmaceuticals, Inc. In phase 1, first-in-human, ascending single-dose, placebo (PBO)-controlled, double-blind study evaluated the safety and efficacy of evinacumab administered subcutaneously (SC) or intravenously (IV) in subjects with elevated TGs (150≤ TG ≤450 mg/dL) and/or LDL-C (≥100 mg/dL). Evinacumab effected dose-responsive reductions in TG (maximum reduction on Day 4) with median % changes from baseline of -1.0% to -75.0% from low to high dose vs +9.0% for PBO IV [p<0.0001]) and LDL-C (mean % changes of LDL-C from baseline on Day 11 were -3.4% to -25.5% from low to high dose vs -0.4% for PBO IV [p=0.0013]).

References[edit]